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six months, the mean reduction in tHcy was slightly but signifi-Hyperhomocysteinemia in hemodialysis patients: Effects of 12-
cantly greater for patients receiving intravenous folic acid (12.2 6month supplementation with hydrosoluble vitamins.
18.5 mmol/L) compared with patients not receiving it (8.3 6Background. High-efficiency hemodialysis may induce a
9.8 mmol/L, P , 0.05). However, at 12 months, no differencedeficiency in hydrosoluble vitamins. Supplementation with
between both subgroups persisted. When considering the dif-B-complex vitamins has been shown to lower serum homocys-
teine concentrations in several groups, but relatively few stud- ferent genotypes, tHcy at baseline tended to be higher for TT
ies have concerned hemodialysis patients. Our objectives were than CT and CC (39.8 6 30.9 vs. 31.4 6 10.5 vs. 31.6 6 11.8
to determine the status in B-complex vitamins in a large cohort mmol/L) and decreased to respective values of 21.1 6 6.9 versus
of unsupplemented hemodialysis patients and to assess the 21.4 6 6.1 versus 22.2 6 5.9 mmol/L at 12 months. The impact
effects of supplementation with hydrosoluble vitamins on se- of the addition of folic acid to DiaVitet appeared particularly
rum homocysteine over one year. significant in TT patients at six months.
Methods. Serum total homocysteine (tHcy), vitamin B12, fo- Conclusions. (1) Hyperhomocysteinemia was present in
late, pyridoxal-59-phosphate (P-59-P; the active moiety of vita- 100% of our hemodialysis patients. (2) Nearly 40% of our
min B6), as well as red blood cell folate concentrations, were unsupplemented hemodialysis patients were deficient in vita-
measured in 168 chronic dialysis patients on three times weekly min B6. (3) Supplementation with DiaVitet has resulted in
high-efficiency hemodialysis and not supplemented with hydro- significant tHcy reductions for all three genotypes. (4) The
soluble vitamins. Their methylenetetrahydrofolate reductase impact of the proposed supplementation protocol was found
C677T (MTHFR) genotypes were also determined (homozy- after six months and was maintained, but did not increase
gotes TT, heterozygotes CT, without mutation CC). All in- further after 12 months of the same regimen. (5) The addition
volved patients were then supplemented with hydrosoluble of intravenous folic acid has been associated with a more pro-
vitamins (once daily by mouth, DiaVitet; R&D Laboratories, nounced decrease in tHcy in TT patients.
Minneapolis, MN, USA), and half of them were randomized
to receive in addition 10 mg intravenously of folic acid posthe-
modialysis (30 mg intravenously per week). Serum tHcy was
Hyperhomocysteinemia is now recognized as an inde-monitored after 6 and 12 months of supplementation in the
140 and 128 patients available for follow-up. pendent risk factor for atherosclerotic cardiovascular dis-
Results. At baseline, serum and red blood cell folate concen- eases in the general population [1–5]. There is a higher
trations were within normal limits in all patients except for
prevalence of hyperhomocysteinemia in end-stage renaltwo with borderline serum folate (mean values of 21 6 8 and
disease (ESRD) patients who are predialysis and on dial-1195 6 454 nmol/L), whereas serum vitamin B12 and P-59-P
were below normal in 11 and 65 patients, respectively (mean ysis [6, 7], as well as in renal transplant patients [8, 9].
values of 327 6 215 pmol/L and 19 6 16 nmol/L for the 168 In both populations, the increased incidence of athero-
patients). Initial tHcy levels were increased in all patients sclerotic vascular disease has been shown to correlate(mean 33.3 6 16.6 for a normal below 11.8 6 1.5 mmol/L);
with the level of serum homocysteine [9–13]. Moreover,tHcy significantly decreased to 23.5 6 7.6 mmol/L after six
ESRD patients have serum total homocysteine (tHcy)months (P , 0.0001 vs. baseline) and to 21.7 6 6.1 mmol/L
after 12 months (P , 0.0001 vs. baseline) for the entire group, values twofold to threefold higher than those of age-
but was normalized in only four patients at 12 months. After matched controls with normal renal function [14, 15].
Recognized causes of hyperhomocysteinemia include
deficiencies or mutation of enzymes involved in the me-Key words: homocysteine, folate, vitamin B12, pyridoxal-59-phosphate,
atherosclerotic cardiovascular disease, end-stage renal disease. tabolism of methionine, deficiencies in various cofactors
involved in the metabolism of homocysteine, and renal
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alone or in combination, has been successful in reducing France) at a blood flow rate of 350 to 450 mL/min and
a dialysate flow rate of 500 to 600 mL/min.homocysteine concentrations to various degrees in dif-
ferent subgroups of patients [16–22]. Although a reduc-
Blood sampling and vitamin supplementationtion in serum homocysteine has been associated with
None of the involved patients were receiving vitaminfewer atherothrombotic events in patients afflicted by
supplementation at study entry, since it had not been athe genetic disorder homocystinuria [23, 24], its benefit
routine practice in our unit for more than five years. Atremains to be proven for milder degrees of hyperhomo-
the beginning of the study, baseline values of serumcysteinemia such as that which occurs in chronic renal
tHcy, serum vitamin B12, serum folate, serum pyridoxal-failure patients.
59-phosphate (P-59-P, the active moiety of vitamin B6),On the other hand, patients on hemodialysis are at
and red blood cell folate were measured in all patients.risk for deficiency in hydrosoluble vitamins as a conse-
Thereafter, all patients were supplemented with hy-quence of either poor intake, decreased absorption, al-
drosoluble vitamins orally (DiaVitet once daily takentered metabolism, and/or dialysis-induced losses [25–27].
by mouth; R&D Laboratories, Marina del Rey, CA,High-flux hemodialysis may further decrease serum con-
USA; note that Nephro-Vitet is marketed in Canada ascentrations of hydrosoluble vitamins [27, 28], while
DiaVitet). Moreover, half of the patients were random-erythropoietin therapy may precipitate folate and vita-
ized to receive an additional 10 mg of folic acid intrave-min B12 deficiencies [29, 30]. Most of the studies that
nously posthemodialysis, and hence were administeredhave addressed the impact of vitamin supplementation
30 mg intravenously per week. Measurements of serumon homocysteine levels in ESRD patients were per-
tHcy, folate, vitamin B12, and P-59-P were repeated afterformed over short time periods [31–40], with only one
6 and 12 months of supplementation. The MTHFR geno-recent study reporting results over one year [41]. More-
type status of our patients was also determined.over, chronic renal disease is associated with a relative
DiaVitet is a hydrosoluble multivitamin formulationresistance to the lowering effects of low-dose folate sup-
containing per capsule 1 mg of folic acid, 10 mg of pyri-plementation on homocysteine [36, 42]. Whereas 1 to 5
doxine (vitamin B6), and 6 mg of cobalamin (vitaminmg/day of folic acid may normalize plasma homocysteine
B12). It also contains ascorbic acid (vitamin C, 60 mg),in moderately hyperhomocysteinemic individuals with
thiamine (vitamin B1, 1.5 mg), riboflavin (vitamin B2, 1.7normal renal function, a similar effect has not been ob-
mg), nicotinic acid (20 mg), panthothenic acid (10 mg),served in ESRD patients. Hence, the optimal dose as
and biotin (300 mg).well as the ultimate benefits remain to be clearly demon-
strated in chronic dialysis patients. Homocysteine assay
The purpose of the present study was to assess the
Total homocysteine serum concentrations (comprising
effects of enteral (6 parenteral) supplementation with both free and protein-bound forms) were obtained predi-
hydrosoluble vitamins on serum homocysteine concentra- alysis. After drawing, blood was placed immediately on
tions in a large cohort of chronic hemodialysis patients ice, and serum was separated promptly by centrifugation
over a one year interval. Concomitantly, the methylene- at 3000 r.p.m. The serum fraction was removed and then
tetrahydrofolate reductase (MTHFR) genotype of our stored at 2808C until assayed. Total serum homocysteine
group of patients was determined, since a mutation of this levels were measured using high-performance liquid
enzyme is commonly related to hyperhomocysteinemia chromatography (HPLC) with fluorometric detection as
[43]. This allowed us to evaluate the impact of supple- recently described [44]. This method allows the simulta-
mentation with hydrosoluble vitamins for the different neous measurement of other thiols found in serum (cys-
genotypes of this enzyme prevailing in our hemodialysis teine, cysteinylglycine, and glutathion). Normal values
population. are below 11.8 6 1.5 mmol/L for males and below 10.9 6
2.0 mmol/L for females.
METHODS Serum measures of B-complex vitamins
Patients and hemodialysis technique Serum folate and vitamin B12 were determined by im-
One hundred sixty-eight chronic dialysis patients were munochemiluminescence (Access Immunoassay Instru-
initially enrolled in the study after informed consent. All ments, Beckman, Mississauga, Canada). Normal values
patients were on hemodialysis at the beginning of the for folate and vitamin B12 were .10 nmol/L and 190 to
study in May 1998, with a regimen including three times 730 pmol/L, respectively, whereas values compatible
weekly sessions (3.5 to 4 hours each) using high-effi- with frank deficiencies are ,7 nmol/L and ,150 pmol/L,
ciency reused dialyzers (CT190, Dicea170, Tricea210; respectively. P-59-P, the active moiety of vitamin B6, was
Baxter, McGaw Park, IL, USA; or F8, F80; Fresenius, measured by radioenzymatic assay (vitamin B6 3H REA;
Bu¨hlmann Laboratories, American Laboratory Products,Bad Homburg, Germany; or Filtral 20, Hospal, Lyon,
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Table 2. Concentrations of B-complex vitamins and homocysteineTable 1. Baseline characteristics of patients randomized
for IV folic acid over the study period for all patients, and by subgroups
with or without folic acid
Folic acid IV No folic acid IV
Baseline 6 months 12 months
Number 83 85
Age years 60.2614.1 61.4613.8 RBC folate nmol/L
All 1195.16454.0Sex ratio male/female 50/33 49/36
Diabetes N of patients 24 26 1Folic acid 1156.66417.2
2Folic acid 1235.76488.9Causes of ESRD
Diabetes 18 12 Serum folate nmol/L
All 20.8467.62Glomerular diseases 16 16
Ischemic renal diseases 11 14 1Folic acid 20.4367.34 all.45a
2Folic acid 21.2667.93 43.4165.13aHypertensive nephrosclerosis 12 15
Chronic pyelonephritis 4 6 Vitamin B12 pmol/L
All 326.96215.2 493.76488.4aPolycystic disease 9 5
Other 5 12 1Folic acid 319.36228.8 531.46650.9a
2Folic acid 334.66202.0 449.66149.2aUnknown 8 5
Time on dialysis year 3.464.6 3.063.8 P-59-P nmol/L
All 19.1615.6 128.8697.4aMean single pool Kt/V 1.6460.30 1.7260.37
Mean serum albumin g/L 38.464.4 38.265.4 1Folic acid 18.2615.2 125.2699.5a
2Folic acid 20.0616.1 129.1695.8aVascular disease N of patients 47 46
History of access thrombosis tHcy lmol/L
All 33.27616.59 23.5467.56a 21.6966.12aN of patients 18 22
Active smoking N of patients 41 22 1Folic acid 34.75619.96 22.6667.60ab 21.6966.94a
2Folic acid 31.83612.39 24.6267.48a 21.6965.00aNo difference in both subgroups except for the prevalence of active smoking
(P 5 0.02). Abbreviations are: RBC, red blood cells; P-59-P, pyridoxal-59-phosphate; tHcy,
total homocysteine.
aP , 0.0001 vs. baseline
bP , 0.05 for 1folic acid vs. 2folic acid
Windham, NH, USA); normal values for P-59-P were
between 11.5 and 179.3 nmol/L (as reported by the manu-
facturer). Red blood cell folate was obtained using the to peritoneal dialysis (7), renal transplantation (7), and
same method as for serum folate but applied after cell transfer to another dialysis center (2). At 12 months, 12
lysis. Normal values were between 375 and 2500 nmol/L, more patients (7%) were lost at follow-up as a conse-
and values compatible with deficiency were ,125 nmol/L. quence of death (7), switch to peritoneal dialysis (2),
renal transplantation (2), and transfer to another center
MTHFR genotype determination (1). None were withdrawn from the study for side effects
of vitamin supplementation. All patients were includedThe polymerase chain reaction primers for the ampli-
in the baseline analysis, and therefore, 140 patients re-fication of the MTHFR mutation have been described
mained in the analysis at 6 months and 128 patients atelsewhere [45]. If the MTHFR mutation is present, HinfI
12 months.digests the 198 bp fragment into a 175 bp and a 23 bp
Table 2 shows the evolution of serum folate, vitaminfragments. Analyzing the fragments in 2.5% polyacryl-
B12, P-59-P, tHcy, and red blood cell folate concentrationsamide gel electrophoresis allows the determination of
over the study period in all patients involved in the studythe length of the fragments.
and by subgroups receiving or not receiving folic acid.In the next section, results are presented as mean 6
At baseline, serum and red blood cell folate levels wereSD. Statistics applied were analysis of variance or paired
within normal limits in all unsupplemented patients, ex-or unpaired Student’s t-test, where appropriate.
cept for two patients having borderline serum folate
(above 7 but below 10 nmol/L). Although the mean value
RESULTS of serum vitamin B12 was also within normal limits (326.9 6
At baseline, there were 99 males and 69 females with 215.2 pmol/L), 11 patients (6%) were deficient, having
a mean age of 60.8 6 7.2 years; they had been on hemodi- values below 150 pmol/L at baseline. P-59-P was below
alysis for an average of 3.2 6 0.9 years. In the preceding normal in a large proportion of patients at the start (65
months, their mean Kt/V and nPCR (normalized protein patients or 39%), with initial mean and median values
catabolic rate) were, respectively, 1.68 6 0.06 and 0.95 6 of 19.1 6 15.6 and 16.7 nmol/L for the entire group.
0.17 g/kg/day. Causes of ESRD are shown in Table 1. Figure 1 shows the distribution of serum P-59-P in our
Demographic parameters for the two subgroups follow- unsupplemented patients at study entry. After 12 months
ing randomization for intravenous folic acid are also of supplementation with DiaVitet, the median was in-
presented in Table 1. creased to 106.6 nmol/L, and only 5 patients had P-59-P
After 6 months, 28 patients (17%) were lost at follow- values below the lower normal limit (suggesting either
poor absorption and/or compliance).up for the following reasons: death (N 5 12), switch
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Fig. 1. Distribution of serum pyridoxal-59-
phosphate (P-59-P) concentrations (nmol/L)
in the 168 unsupplemented hemodialysis pa-
tients at study entry (one bar per patient).
Fig. 3. Evolution of total serum homocysteine (mmol/L) over 12 monthsFig. 2. No significant relation was observed between serum total homo-
of the described vitamin regimen (DiaVitet 1 daily by mouth 6 foliccysteine (tHcy; mmol/L) and serum folate (nmol/L) concentrations in
acid intravenously 30 mg per week) in the 128 patients available atour unsupplemented hemodialysis patients at baseline. y 5 25.6 Ln(x) 1
follow-up. y 5 210.0x 1 50.7; R2 5 0.58; P , 0.0001.50.0; R2 5 0.014.
At baseline, tHcy serum concentrations were above serum tHcy was normalized in only four patients at 6
months and in four patients at 12 months (only 1 patientnormal values in all our patients (100%), ranging from
12.01 to 158 mmol/L (mean of 33.3 6 16.6 mmol/L and included at both times), of whom seven (over 8) were
receiving intravenous folic acid. There was no furthermedian of 29.7 mmol/L). Despite an observed tendency,
there was no significant negative correlation between significant decrease in tHcy at 12 months (with or without
folic acid). Figure 3 presents serial tHcy serum concen-initial tHcy and serum folate concentrations in our un-
supplemented hemodialysis patients (Fig. 2). After 6 trations (at time 0, 6, and 12 months) for the 128 patients
remaining in the study at 12 months.months of supplementation with DiaVitet, tHcy serum
concentrations decreased significantly to a mean of The distribution of MTHFR genotypes obtained for
161 of the involved hemodialysis patients was as follows:23.5 6 7.6 mmol/L for the remaining 140 patients (P ,
0.0001). In addition, the mean reduction in tHcy tended 68 patients (42%) had no mutation (CC); 67 (42%) were
heterozygotes (CT), and 26 (16%) were homozygotesto be higher in the subgroup also receiving intravenous
folic acid, but the difference did not reach significance. (TT). Among CC, 35 were randomized to intravenous
folic acid, among CT, 34, and finally, among TT, 13We found a mean reduction of tHcy of 12.2 6 18.5
mmol/L for those supplemented with intravenous folic patients. Baseline tHcy, as well as changes in tHcy values,
was found to be slightly different in the subgroup analysisacid as a group compared with 8.1 6 9.7 mmol/L for
those without the intravenous supplementation at six by genotypes. Table 3 shows tHcy values at baseline, at
6, and at 12 months for each MTHFR genotype (formonths (P , 0.05). At 12 months, no further difference
in tHcy between both subgroups was found. However, patients remaining in the study at 12 months). Hence,
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Table 3. Evolution of total homocysteine (tHcy) for the different ing only folic acid supplementation [26], as well as the
MTHFR genotypes
work of Robinson et al, who showed that deficiency in
Baseline 6 months 12 months vitamin B6 was more frequent in ESRD patients than in
No mutation (CC) the normal reference population [47]. The present study
All 31.65611.79 24.6467.93a 22.2265.92a shows that 10 mg daily of pyridoxine normalizes P-59-P
1Folic acid 34 34.02612.35 24.7368.32ab 22.6466.94a
serum concentrations in a large group of chronic hemodi-2Folic acid 28 30.47612.10 24.8567.40a 21.6964.01a
Heterozygotes (CT) alysis patients, and this highlights the increased require-
All 31.38610.46 22.2767.29a 21.3666.13a ments in pyridoxine of such a population.
1Folic acid 28 31.5869.83 21.4965.71ab 20.9466.16a
Although hemodialysis patients rarely present folate2Folic acid 31 32.42612.03 23.1368.45a 21.8566.07a
Homozygotes (TT) deficiency, an inverse correlation between serum folate
All 39.79630.89 23.4567.13a 21.0666.89a and serum homocysteine has been demonstrated pre-
1Folic acid 11 51.55631.83 21.8268.86ac 22.6069.06a
viously [48]. Only a tendency, and no significant inverse2Folic acid 12 32.2066.08 24.9465.04a 19.8064.51a
correlation, was observed in our unsupplemented pa-aP , 0.0001 vs. baseline
bP , 0.05 vs. 2folic acid tients at enrollment in the study. Nonetheless, it has
cP , 0.01 vs. 2folic acid been proposed that these “normal” baseline serum folate
concentrations probably do not suffice for lowering hyp-
erhomocysteinemia in ESRD [34]. Therefore, investiga-
tors have begun to give supraphysiologic doses of folicmean tHcy values at baseline tended to be higher for
acid in an attempt to decrease homocysteine levels [17,homozygotes (TT, 39.8 6 30.9 mmol/L) than for hetero-
21, 22]. In hemodialysis patients, a dose of 1 mg dailyzygotes (CT, 31.4 6 10.5 mmol/L) or patients without
by mouth of folic acid has been shown sufficient to nor-the mutation (CC, 31.6 6 11.8 mmol/L). Subsequent anal-
malize plasma folate concentrations [26] and thus hasysis at six months showed diminution of tHcy levels to
been advocated; however, such a dose has never been23.4 6 7.1 versus 22.3 6 7.3 versus 24.6 6 7.9 mmol/L,
shown to normalize homocysteine in ESRD patients [25].respectively. At 12 months, tHcy values for respective
House and Donnelly gave a standard multivitamin sup-genotypes (21.1 6 6.9 vs. 21.4 6 6.1 vs. 22.2 6 5.9 mmol/L)
plement daily (Nephro-Vitet marketed in Canada aswere similar to those found at six months. The evolution
DiaVitet and containing 1 mg of folic acid) to 11 chronicof tHcy is also presented according to the two arms of
hemodialysis patients during three weeks [49]; homocys-the study, with and without intravenous folic acid. The
teine levels decreased by more than 20%. Dierkes et aladdition of folic acid to DiaVitet did result in a further
recently reported the results of a study comparing 2.5decrease, although small, in tHcy at six months, particu-
to 5 mg of folic acid by mouth in hemodialysis and perito-larly in homozygotes for MTHFR in whom the most
neal dialysis patients [50]; they found that both supple-significant impact was observed (P 5 0.036; Fig. 4).
mentation regimens reduced homocysteine to the same
degree, by nearly 35%. Van Guldener et al measured
DISCUSSION homocysteine concentrations in 26 hemodialysis patients
randomized to receive either 1 or 5 mg daily by mouthDialysis patients are at increased risk for deficiencies
in hydrosoluble vitamins [25, 46], since hemodialysis is of folic acid after 52 weeks [41]; at the end of the study,
homocysteine levels did not differ significantly betweenassociated with a relatively high removal rate of water-
soluble vitamins. Potential losses are even more pro- both groups.
The rationale for giving supraphysiologic doses of folicnounced in patients undergoing high-flux or high-effi-
ciency hemodialysis, as shown recently by Kasama et al acid is that it serves as a methyl donor in the remethyla-
tion reaction of homocysteine metabolism and is “con-for vitamin B6 [27]. Our results confirm that a significant
proportion of chronic hemodialysis patients are deficient sumed” in that reaction. Therefore, by providing a
greater amount of folic acid, one can further lower homo-in vitamin B6 if not supplemented (65 patients, or nearly
40%, with overt deficiencies and 61 more patients, or cysteine levels towards normal. Bostom et al have given
as much as 15 mg/day of folic acid without side effects36%, with borderline values, defined as between 11.5
and 25.5 nmol/L). A normal folate status was found in [33]. However, the optimal dose of folic acid required
to normalize serum homocysteine, or else, that providesalmost all of our unsupplemented patients despite sub-
stantial folate losses during hemodialysis; however, a the maximal impact on hyperhomocysteinemia remains
unknown at this point. During the study, our patientsfunctional deficit was not excluded. Serum vitamin B12
was normal in all but five patients at baseline. These were all supplemented with an enteral mixture of hydro-
soluble vitamins in the form of DiaVitet, containing 1 mgresults are similar to those of Descombes, Hanck, and
Fellay, who found a vitamin B6 deficiency in up to 89% of folic acid. Since the content of DiaVitet in folic acid
is relatively small, it was decided to randomize patientsof unsupplemented patients, and normal serum folate
and vitamin B12 concentrations in dialysis patients receiv- to receive an additional amount of 10 mg intravenous
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Fig. 4. Serum total homocysteine (tHcy;
mmol/L) over 12 months for hemodialysis pa-
tients homozygous for MTHFR who received
both oral DiaVitet and intravenous folic acid.
Eleven patients were available for the entire
follow-up. Each patient is represented with a
different bar type.
of folic acid at each dialysis session (or 30 mg/week). gotes (TT) presented the highest tHcy concentrations at
baseline, as well as the greater reduction in tHcy levelsSuch a regimen was considered practical from a clinical
trial standpoint. After one year of this regimen, respec- as a group (41.2%), but nevertheless ended up after 12
months with final tHcy values similar to the patients withtive reductions of 37.5 and 31.8% in serum tHcy concen-
trations compared with baseline values were observed either normal (CC) or heterozygous (CT) genotypes.
Many nonrenal-failure individuals homozygous for thein patients receiving and not receiving intravenous folic
acid. Therefore, although present, the effect of the addi- MTHFR mutation have normal serum homocysteine lev-
els; it has been proposed that the homozygous genotypetion of folic acid to DiaVitet does not seem major.
Besides folic acid, the impact of a supplementation is not necessarily associated with hyperhomocysteinemia
except if a concomitant deficiency in folate occurs [43].with the other B-complex vitamins such as B6 and B12 is
more difficult to assess. Several clinical trials looking at Thus, individuals homozygous for the mutation may have
higher folate requirements for the regulation of plasmathe impact of B-complex vitamin supplementation in
hyperhomocysteinemic subjects have found that combin- homocysteine. Interestingly, other investigators have
shown that the folate status and the MTHFR mutationing folic acid, vitamin B6, and vitamin B12 may reduce
further the homocysteine concentration when compared interact at a much higher folate level in dialysis patients
(folate 29.2 ng/mL) when compared with a populationwith isolated supplementation with folic acid, B6, or B12
[17, 20, 21]. The impact of vitamin B6 alone (in doses of with normal renal function (folate 6.8 ng/mL) [48]. Even
though our patients had a normal folate status at the10 mg daily of pyridoxine resulting in a 5% homocysteine
reduction) appears smaller than that of folic acid alone beginning of the study, those with the homozygous geno-
type had higher homocysteine values and appeared more(5 mg daily causing 45 to 50% decrease) [20]. Several
studies have shown reductions in homocysteine levels of responsive to additional intravenous folic acid after six
months.30 to 50% with various B-complex multivitamin regi-
mens, whereas others have shown similar decreases with To summarize, (1) hyperhomocysteinemia was present
in 100% of our 168 chronic hemodialysis patients. (2)folic acid alone. However, most of these trials concerned
hyperhomocysteinemic patients not on dialysis. Since The distribution of their MTHFR genotypes appeared
comparable to the one prevailing in the French Canadianhemodialysis patients are not only hyperhomocysteine-
mic as a group, but also at risk for deficiencies in hydro- population. (3) Considering the entire unsupplemented
group at baseline, nearly 40% of our patients were defi-soluble vitamins, it seems even more appropriate to sup-
plement them aggressively. cient in vitamin B6. Few of them presented low serum
concentrations of vitamin B12, and most of them had aA mutation (an alanine-to-valine substitution, T to C)
in MTHFR renders it thermolabile and may be associ- normal folate status. (4) Supplementation with DiaVitet
(with or without added intravenous folic acid) has re-ated with elevated levels of homocysteine [45]. The inci-
dence of the MTHFR mutation genotypes in our hemo- sulted in very significant tHcy reductions in serum tHcy
for all three genotypes (by more than 29% at 6 monthsdialysis population is very similar to the reported
incidence in the general population [45]. We observed and by close to 35% at 12 months). (5) The impact of
the proposed supplementation protocol was found aftera slightly different degree of reduction of serum homo-
cysteine for the different MTHFR genotypes. Homozy- 6 months and was maintained but did not increase further
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8. Bostom AG, Gohn RY, Tsai MY, Hopkins-Garcia BJ, Nadeauafter 12 months of the same regimen. (6) The addition
MR, Bianchi LA, Jacques PF, Rosenberg IH, Selhub J: Excess
of intravenous folic acid has been associated with a more prevalence of fasting and postmethionine loading hyperhomocys-
teinemia in stable renal transplant recipients. Arterioscler Thrombpronounced decrease at six months, particularly in TT
Vasc Biol 17:1894–1900, 1997patients. However, further benefits were not clearly ob-
9. Massy ZA, Chadefaux-Vekemans B, Chevalier A, Bader CA,
served thereafter. Drueke TB, Legendre C, Lacour B, Kamoum P, Kreiss H: Hyper-
homocysteinemia: A significant risk factor for cardiovascular dis-The present study was not designed to assess the ef-
ease in renal transplant recipients. Nephrol Dial Transplant 9:1103–fects of supplementation with folic acid, vitamin B6, or 1108, 1994
vitamin B12 separately; therefore, the potential impact 10. Makoff R, Dwyer J, Rocco MV: Folic acid, pyridoxine, cobalamin
and homocysteine and their relationship to cardiovascular diseaseof each compound cannot really be determined. How-
in end-stage renal disease. J Ren Nutr 6:2–11, 1996ever, our results, obtained in a large cohort of chronic
11. Bachman J, Tepel M, Raidt H, Riezer R, Grafe U, Langer K,
hemodialysis patients followed over one year, suggest Zidek W: Hyperhomocysteinemia and the risk of vascular disease
in hemodialysis patients. J Am Soc Nephrol 6:121–125, 1995that a hydrosoluble multivitamin enteral formulation,
12. Kim SS, Hirose S, Tamura H, Nagasawa R, Tokushima H, Mi-such as DiaVitet, is desirable in ESRD patients treated
tarai T, Isoda K: Hyperhomocysteinemia as a possible role for
by high-efficiency hemodialysis to normalize serum con- atherosclerosis in CAPD patients. Adv Perit Dial 10:282–285, 1994
13. Moustafa A, Naso A, Nahlawi M, Gupta A, Arheart KL, Jacob-centrations of B-complex vitamins. Its administration
sen DW, Robinson K, Dennis VW: Prospective study of hyperho-leads to very significant reductions in serum tHcy, which
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